Patents Assigned to The General Hospital Corporation, a Massachusetts corporation
  • Publication number: 20030068612
    Abstract: Disclosed are methods for identifying molecular interactions (e.g., protein/protein, protein/DNA, protein/RNA, or RNA/RNA interactions). All of the methods within the invention employ counterselection and at least two hybrid molecules. Molecules which interact reconstitute a transcription factor and direct expression of a reporter gene, the expression of which is then assayed. Also disclosed are genetic constructs which are useful in practicing the methods of the invention.
    Type: Application
    Filed: June 26, 2002
    Publication date: April 10, 2003
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Marc Vidal, Jef D. Boeke, Ed Harlow
  • Publication number: 20030059848
    Abstract: The invention is based, in part, on the discovery that the CRY proteins and the PER2 protein function as important modulators of mammalian circadian rhythm. The invention includes methods of modulating the circadian rhythm and identifying compounds that modulate the circadian rhythm.
    Type: Application
    Filed: September 17, 2002
    Publication date: March 27, 2003
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Steven M. Reppert, David R. Weaver, Mark Zylka, Xiaowei Jin, Kazuhiko Kume, Sriram Sathyanarayanan, Lauren Shearman
  • Publication number: 20030044395
    Abstract: The invention relates to microfabricated membranes and matrices that have a highly controlled and complex three-dimensional topography. The new microfabricated membranes and matrices can be prepared of man-made as well as natural materials, such as materials found in naturally occurring membranes, and thus can be made in the form of tissue substitutes or analogs, such as basal lamina, dermal, or skin analogs.
    Type: Application
    Filed: October 8, 2002
    Publication date: March 6, 2003
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Jeffrey R. Morgan, George D. Pins
  • Publication number: 20030017142
    Abstract: The invention features-modular cell culturing devices including one or more flat-plate modules, and is based on the discovery that if the flows of liquid medium and oxygenated fluid are separated by a gas-permeable, liquid-impermeable membrane, and the cells are grown attached to the liquid side of the membrane, the device can be used to culture cells with transport of oxygen through the membrane (i.e., direct oxygenation), without regard for the flow rate of the liquid medium passing through the device. The new flow-through cell culturing devices can thus be used to culture cells, e.g., hepatocytes, with high levels of cell function in organ, e.g., liver, assist systems, for production of cells, for production of cell-derived products, such as, proteins or viruses, or for systems to treat biological liquids to remove toxins, such as, ammonia, or add cell-synthesized products, or both.
    Type: Application
    Filed: July 15, 2002
    Publication date: January 23, 2003
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Mehmet Toner, Arno W. Tilles, Ulysses J. Balis, Martin L. Yarmush, Maury D. Cosman, Paul A. Dimilla
  • Publication number: 20020197627
    Abstract: Disclosed are methods for identifying molecular interactions (e.g., protein/protein, protein/DNA, protein/RNA, or RNA/RNA interactions). All of the methods within the invention employ counterselection and at least two hybrid molecules. Molecules which interact reconstitute a transcription factor and direct expression of a reporter gene, the expression of which is then assayed. Also disclosed are genetic constructs which are useful in practicing the methods of the invention.
    Type: Application
    Filed: March 27, 2002
    Publication date: December 26, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Marc Vidal, Jef D. Boeke, Ed Harlow
  • Publication number: 20020187124
    Abstract: The invention features methods for treating liver disease (e.g., viral hepatitis) by administering an asialocytokine (e.g., asialointerferon). The invention also includes methods of targeting a glycoprotein to a hepatocyte and a composition containing an asialocytokine.
    Type: Application
    Filed: March 29, 2002
    Publication date: December 12, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventor: Hiroshi Takahashi
  • Publication number: 20020151517
    Abstract: A method of inhibiting neoplastic cell growth in a mammal by administering to the mammal nucleosomes that elicit the production of antinuclear autoantibodies sufficient to inhibit neoplastic cell growth.
    Type: Application
    Filed: April 9, 2002
    Publication date: October 17, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Vladimir P. Torchilin, Leonid Z. Iakoubov
  • Publication number: 20020142297
    Abstract: Described are short peptide sequences, termed recombinant peptide chelates (RPCs), and the imaging marker genes that encode them. The RPCs can be expressed in parallel with the expression of any other desired gene (e.g., a therapeutic gene), and used to easily confirm the expression of the therapeutic gene product. The RPCs are expressed in the cell or on the cell surface concurrently with the therapeutic gene product, and can be assayed by standard imaging techniques.
    Type: Application
    Filed: December 18, 2000
    Publication date: October 3, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Alexei A. Bogdanov, Ralph Weissleder, Maria Simonova
  • Publication number: 20020119189
    Abstract: A method of inhibiting neoplastic cell growth in a mammal by administering to the mammal nucleosomes that elicit the production of antinuclear autoantibodies sufficient to inhibit neoplastic cell growth.
    Type: Application
    Filed: February 22, 2002
    Publication date: August 29, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Vladimir P. Torchilin, Leonid Z. Iakoubov
  • Publication number: 20020062101
    Abstract: A method for delivering compounds through epithelial cell layers using impulse transients is described. The method involves applying a compound to, e.g., the stratum corneum, of a patient and then inducing impulse transients to create transient increases in the permeability of epithelial tissue, thereby facilitating delivery of the compound across the epithelial cell layer.
    Type: Application
    Filed: June 25, 2001
    Publication date: May 23, 2002
    Applicant: The General Hospital Corporation, Massachusetts corporation
    Inventors: Nikiforos Kollias, Apostolos G. Doukas, Thomas J. Flotte, Daniel J. McAuliffe, Shun Lee
  • Publication number: 20020052483
    Abstract: Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistent to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases and other insults.
    Type: Application
    Filed: March 16, 2001
    Publication date: May 2, 2002
    Applicant: The General Hospital Corporation, Massachusetts corporation
    Inventor: Daniel K. Podolsky
  • Publication number: 20020032307
    Abstract: The invention features fragments of hepadnavirus pre-S protein that bind to viral receptor p120 or p170.
    Type: Application
    Filed: March 27, 2001
    Publication date: March 14, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Shuping Tong, Jisu Li, Jack R. Wands
  • Publication number: 20020009417
    Abstract: A method of inhibiting neoplastic cell growth in a mammal by administering to the mammal nucleosomes that elicit the production of antinuclear autoantibodies sufficient to inhibit neoplastic cell growth.
    Type: Application
    Filed: April 5, 1999
    Publication date: January 24, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: VLADIMIR P. TORCHILIN, LEONID Z. IAKOUBOV
  • Publication number: 20010041342
    Abstract: In accordance with the invention, Bcl-2 expression is a molecular marker for muscle stem cells. Thus, the invention provides methods for identifying and isolating muscle stem cells. In addition, the invention provides methods for determining whether a test compound modulates muscle stem cell differentiation and/or proliferation. Finally, the invention provides methods for expressing an exogenous coding sequence in a muscle stem cell.
    Type: Application
    Filed: July 19, 2001
    Publication date: November 15, 2001
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventor: Jeffrey B. Miller
  • Publication number: 20010039261
    Abstract: The present invention relates to the treatment of central nervous system injuries by intracisternal or intravenous administration of polypeptide growth factors, such as basic fibroblast growth factor. This method provides significant benefits because administration can occur a substantial amount of time following an injury.
    Type: Application
    Filed: April 10, 2001
    Publication date: November 8, 2001
    Applicant: The General Hospital Corporation, Massachusetts Corporation
    Inventor: Seth P. Finklestein
  • Publication number: 20010024794
    Abstract: The invention provides a method of using a reporter gene that encodes a fluorescent polypeptide to indicate that an interaction has occurred between a bait and a prey protein in a mammalian cell. An advantage of using a fluorescent reporter polypeptide is that an interaction between a bait and prey in a mammalian cell can be readily detected, e.g., within 96 hours. In another method of the invention, a prey plasmid contains an Epstein-Barr virus origin of replication (ori-P). The OriP permits the prey plasmid to replicate episomally and indefinitely without damaging the mammalian cell or integrating into the genomic DNA of the mammalian cell. Since such a plasmid is maintained episomally in a circular form, it can be readily recovered from the mammalian cell.
    Type: Application
    Filed: June 7, 2001
    Publication date: September 27, 2001
    Applicant: The General Hospital Corporation, Massachusetts corporation
    Inventors: Toshihiro Shioda, Kurt J. Isselbacher